Netherlands-headquartered Nucletron,
which produces and services cancer treatment technology, has
developed an international partnership with international lessor De
Lage Landen (DLL), and expects the potential for leasing in this
sub-sector of the health care industry to grow further in the
coming months.
Reender Beks, CFO for Nucletron’s US
branch, said: “From a vendor perspective, in this current market we
want to offer finance options to customers.”
Go deeper with GlobalData
Beks, who is more familiar with the US
than the European market, expects health care centres to lease some
$10 million (€7.4 million) of Nucletron’s equipment in the US alone
over the next two years.
The agreement with DLL, which exists
on a worldwide basis, has seen some success in Europe, despite the
health service in the region being less commercially aware than its
equivalent in the US, Beks added.
In Europe, financial decisions by
hospitals are taken on a different basis than the US, and often
include capex decisions based on government funding.
Beks said DLL was chosen because of
its international credentials and presence in regions such as South
America which, he said, “is pretty exceptional because not so many
EU and US companies do financing there”.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNucletron’s core products are
a radiation delivery device, and two pieces of software to run
it.
One is a treatment control
station, the robotic part, and the other is a treatment planning
system that works with medical images to find where the cancer is
in the body.
The company has offices in
more than 20 countries and has been delivering solutions to more
than 3,000 institutions since 1975, when it started off as a
one-man company.
Last year, Nucletron
introduced the next generation treatment planning software for
brachyotherapy, a form of radiotherapy where a radioactive source
is placed next to the area requiring treatment, which is
particularly used to treat prostate and cervical cancer.
Antonio Fabrizio
